脂肪肉瘤认识与治疗的最新进展
Recent advances in the understanding and management of liposarcoma.
作者信息
Haddox Candace L, Riedel Richard F
机构信息
Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.
Duke Cancer Institute, Durham, NC, USA.
出版信息
Fac Rev. 2021 Jan 4;10:1. doi: 10.12703/r/10-1. eCollection 2021.
Abstract
Liposarcomas are a common subfamily of soft tissue sarcoma with several subtypes recognized by the World Health Organization: atypical lipomatous tumors (ALT)/well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLPS), pleomorphic liposarcoma (PLPS), and myxoid pleomorphic liposarcoma (MPLPS). Despite shared adipocytic features among liposarcomas, the clinical approach to each subtype differs based on histology, location, clinical behavior, and specific oncogenic drivers. In this review, we highlight subtype-specific molecular features with the potential to generate novel therapies. We discuss recent clinical trials investigating the use of preoperative radiation therapy for retroperitoneal liposarcoma, chemotherapy, small molecule inhibitors, and innovative immunotherapy approaches and describe how we incorporate these advancements into the management of liposarcoma.
摘要
脂肪肉瘤是软组织肉瘤中常见的一个亚类，世界卫生组织认可的有几种亚型：非典型脂肪瘤性肿瘤（ALT）/高分化脂肪肉瘤（WDLPS）、去分化脂肪肉瘤（DDLPS）、黏液样脂肪肉瘤（MLPS）、多形性脂肪肉瘤（PLPS）以及黏液样多形性脂肪肉瘤（MPLPS）。尽管脂肪肉瘤之间存在共同的脂肪细胞特征，但基于组织学、位置、临床行为和特定致癌驱动因素，针对每种亚型的临床治疗方法有所不同。在本综述中，我们重点介绍具有产生新疗法潜力的亚型特异性分子特征。我们讨论了最近关于术前放疗用于腹膜后脂肪肉瘤、化疗、小分子抑制剂以及创新免疫治疗方法的临床试验，并描述了我们如何将这些进展纳入脂肪肉瘤的管理中。
相似文献
1
Recent advances in the understanding and management of liposarcoma.
Fac Rev. 2021 Jan 4;10:1. doi: 10.12703/r/10-1. eCollection 2021.
2
An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.
J Mol Histol. 2024 Jun;55(3):227-240. doi: 10.1007/s10735-024-10195-4. Epub 2024 May 2.
3
Lipomatous tumors.
Monogr Pathol. 1996;38:207-39.
4
Histology driven systemic therapy of liposarcoma-ready for prime time?
Transl Gastroenterol Hepatol. 2018 Nov 23;3:96. doi: 10.21037/tgh.2018.11.01. eCollection 2018.
5
Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study.
Mod Pathol. 2022 Nov;35(11):1644-1655. doi: 10.1038/s41379-022-01107-6. Epub 2022 Jun 7.
6
A contemporary review of myxoid adipocytic tumors.
Semin Diagn Pathol. 2019 Mar;36(2):129-141. doi: 10.1053/j.semdp.2019.02.008. Epub 2019 Feb 28.
7
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Oncol Res Treat. 2022;45(9):525-543. doi: 10.1159/000524939. Epub 2022 May 24.
8
Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
Cancer Cytopathol. 2014 Feb;122(2):128-37. doi: 10.1002/cncy.21362. Epub 2013 Nov 12.
9
What's new in adipocytic neoplasia?
Virchows Arch. 2020 Jan;476(1):29-39. doi: 10.1007/s00428-019-02652-3. Epub 2019 Sep 9.
10
Differences in recurrence and survival of extremity liposarcoma subtypes.
Eur J Surg Oncol. 2018 Sep;44(9):1391-1397. doi: 10.1016/j.ejso.2018.03.028. Epub 2018 Apr 6.
引用本文的文献
1
Histomorphological and molecular characteristics of liposarcoma (Review).
Oncol Lett. 2025 Jul 21;30(4):454. doi: 10.3892/ol.2025.15200. eCollection 2025 Oct.
2
Myxoid Liposarcoma of the Thigh in Early Puerperium-Rare Case Report and Narrative Review.
Diseases. 2025 Jul 14;13(7):220. doi: 10.3390/diseases13070220.
3
Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.
Future Oncol. 2025 Jun;21(14):1797-1807. doi: 10.1080/14796694.2025.2502319. Epub 2025 Jun 4.
4
Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario.
Curr Oncol. 2025 May 9;32(5):273. doi: 10.3390/curroncol32050273.
5
A Rare Case of Atypical Pelvic Retroperitoneal Lipoma Mimicking Liposarcoma; A Case Report and Review of Literature.
Clin Case Rep. 2025 Feb 20;13(2):e70236. doi: 10.1002/ccr3.70236. eCollection 2025 Feb.
6
Myxoid liposarcoma: treatment outcomes, metastatic pattern and volumetric analysis.
Strahlenther Onkol. 2025 Feb 3. doi: 10.1007/s00066-025-02366-3.
7
Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities.
Front Oncol. 2024 Dec 11;14:1484027. doi: 10.3389/fonc.2024.1484027. eCollection 2024.
8
Surgical resection due to poor outcome of the immunotherapy of a relapsed mediastinal liposarcoma: a case report.
Future Sci OA. 2024 May 15;10(1):FSO906. doi: 10.2144/fsoa-2023-0099. eCollection 2024.
9
An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.
J Mol Histol. 2024 Jun;55(3):227-240. doi: 10.1007/s10735-024-10195-4. Epub 2024 May 2.
10
Metastatic Epithelioid Pleomorphic Liposarcoma in the Brain: A Case Report.
Cureus. 2023 Dec 6;15(12):e50066. doi: 10.7759/cureus.50066. eCollection 2023 Dec.
本文引用的文献
1
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032).
Ann Surg Oncol. 2023 Feb;30(2):683-685. doi: 10.1245/s10434-022-12762-z. Epub 2022 Nov 17.
2
Phase II Study of Copanlisib in Patients With Tumors With Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
J Clin Oncol. 2022 May 10;40(14):1552-1561. doi: 10.1200/JCO.21.01648. Epub 2022 Feb 8.
3
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.
JAMA Oncol. 2021 Jan 1;7(1):e205865. doi: 10.1001/jamaoncol.2020.5865. Epub 2021 Jan 21.
4
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2020 Oct;21(10):1366-1377. doi: 10.1016/S1470-2045(20)30446-0. Epub 2020 Sep 14.
5
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.
Oncologist. 2020 Nov;25(11):e1655-e1662. doi: 10.1634/theoncologist.2020-0679. Epub 2020 Aug 20.
6
Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
Crit Rev Oncol Hematol. 2020 Sep;153:103029. doi: 10.1016/j.critrevonc.2020.103029. Epub 2020 Jun 18.
7
A Reappraisal of Superficial Pleomorphic Liposarcoma.
Am J Clin Pathol. 2020 Aug 5;154(3):353-361. doi: 10.1093/ajcp/aqaa045.
8
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18.
9
Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine.
CA Cancer J Clin. 2020 May;70(3):200-229. doi: 10.3322/caac.21605. Epub 2020 Apr 10.
10
Primary anatomical site as a prognostic factor for pleomorphic liposarcoma.
J Cancer Res Clin Oncol. 2020 Jun;146(6):1501-1508. doi: 10.1007/s00432-020-03204-y. Epub 2020 Apr 4.
Zotero 插件